Aclarion, Inc.
ACON · Price history
Price at last available close
$2.04
−$0.34 (-14.29%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Aclarion, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making.
How they make money
Aclarion operates a software-native business model focused on healthcare information services. The company generates revenue primarily by delivering Nociscan reports to customers, recognizing revenue upon the delivery of these diagnostic reports to healthcare providers.
Products & services
Nociscan, a proprietary diagnostic software platform that utilizes magnetic resonance spectroscopy to provide objective data for the evaluation of chronic low back pain.
Brands & revenue mix
Core diagnostic software platform for chronic low back pain evaluation.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Healthcare providersSource
Customer concentration
The company does not disclose specific customer concentration figures in its 2025 annual report.
Suppliers, materials & equipment
- Cloud and Data Hosting Providers — The company relies on third-party cloud infrastructure and data hosting services to support its software-native platform; specific supplier names are unnamed.Source
Strengths
- Proprietary Nociscan technology and intellectual property portfolioSource
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
10
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
35
Poor
Financial Strength
65
Business Quality / Moat
0
Management
40
Growth Quality
50
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
34
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
36/100
Building Historical Record
Model Score 36/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Asset quality scores strongly
- •Insider activity signal is favorable
- •Recent buyback activity is present
- •Share split detected
- •Material dilution — approximately 441.8% share-count growth
- •MAJOR RED FLAG: Reverse split proposed / authorized
- •CRITICAL: Bankruptcy / liquidation risk
- •Valuation is a weaker part of the current profile
Company-specific research
Questions worth answering for ACON
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ACON maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can ACON fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ACON likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for ACON to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ACON's current valuation?
Essential Investment Snapshot
Wall Street Score
10
Opportunity Score
34
Market Cap
$5.9M
P/E Ratio
-0.3
EPS
$-7.60
52-Week High
$12.03
52-Week Low
$1.95
Beta
1.24
Shares Outstanding
2.9M
Total Revenue
$84K
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$5.90
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ACON
Detected from reported data — verify before acting.Share split detected
A recent SEC filing references a reverse stock split/share consolidation. Repeated reverse splits receive progressively harsher score ceilings.
Supporting sourceMaterial dilution — approximately 441.8% share-count growth
Shares outstanding increased approximately 441.8% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 25.
MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCRITICAL: Bankruptcy / liquidation risk
A recent SEC filing contains bankruptcy/liquidation language. Wall Street Score is capped at 10.
Supporting filingHistorical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on ACON.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary Nociscan technology and intellectual property portfolio.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Healthcare Information Services industry.
- −Dependence on reimbursement coverage and regulatory approval for diagnostic codes.
- −History of operating losses and need for additional capital.
- −Shares outstanding increased approximately 441.8% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 25.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
36
Sep 8, 2026
Change
-25.7
points
Current Score
10
Oct 1, 2026
Category Changes
ACON decreased 25.7 points because Capital declined by 4 points.
Negative Contributors
- − Capital declined by 4 points
Projected Score
Projected Score
8
Projected Change
-2.4 points
Preliminary comparable-period financial changes suggest decline of approximately 2.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$2.04
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +65.6%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84K | $76K | $46K | $75K | ···· | ···· | ···· | ···· |
| Cost of Revenue | $354K | $296K | $130K | $76K | ···· | ···· | ···· | ···· |
| Gross Profit | -$270K | -$221K | -$84K | -$324.00 | ···· | ···· | ···· | ···· |
| Research & Development | $1.03T | $1.03T | $889K | $873K | ···· | ···· | ···· | ···· |
| SG&A Expenses | $6.03T | $6.03T | $4.6M | $4.0M | ···· | ···· | ···· | ···· |
| Operating Expenses | $9.4M | $6.8M | $5.4M | $4.9M | ···· | ···· | ···· | ···· |
| EBITDA | -$9.0M | -$7.0M | -$6.3M | -$4.1M | ···· | ···· | ···· | ···· |
| Operating Income | -$9.7M | -$7.1M | -$5.5M | -$4.9M | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $535K | $608K | ···· | ···· | ···· | ···· |
| Income Before Tax | -$9.2M | -$7.2M | -$7.0M | -$4.9M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Net Income | -$9.2M | -$7.2M | -$7.0M | -$4.9M | ···· | ···· | ···· | ···· |
| Basic EPS | $-4.00 | $-13.61 | $-7480.22 | $-79782.00 | ···· | ···· | ···· | ···· |
| Basic Shares | 2.46M | 532K | 943 | 62 | ···· | ···· | ···· | ···· |
| Diluted Shares | 2.46M | 532K | 943 | 62 | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$25208
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.12
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
+27.0%
Margin Change
-2613.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
Potential Score Impact
Positive indicators included revenue growth, cash levels. Pressure indicators included EPS growth, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 30.5%. EPS declined 59.3%. Cash increased 27.0%. Net income margin declined by 2613.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Healthcare Information ServicesNews
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
Aclarion, Inc. (NASDAQ:ACON) Short Interest Update
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)
Rumor Mill · ACON
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial